Lassen Therapeutics
Lassen Therapeutics is a biotech company dedicated to developing innovative antibody therapeutics for fibrosis, rare diseases, and oncology. Their mission is to create transformational medicines by combining innovative science, leading technology, and unmatched know-how. They focus on targeting the IL-11 pathway, a central mediator of fibrosis, with the goal of improving patient outcomes in serious diseases.
Industries
Nr. of Employees
small (1-50)
Lassen Therapeutics
San Diego, California, United States, North America
Products
LASN01
A monoclonal antibody targeting the IL-11 receptor, aimed at treating fibro-inflammatory diseases such as thyroid eye disease (TED) and idiopathic pulmonary fibrosis (IPF).
LASN500
A monoclonal antibody targeting the IL-18 binding protein (IL-18BP), intended for cancer treatment by elevating IL-18 at the tumor site.
LASN01
A monoclonal antibody targeting the IL-11 receptor, aimed at treating fibro-inflammatory diseases such as thyroid eye disease (TED) and idiopathic pulmonary fibrosis (IPF).
LASN500
A monoclonal antibody targeting the IL-18 binding protein (IL-18BP), intended for cancer treatment by elevating IL-18 at the tumor site.